https://zlk.com/pslra-1/lantheus-holdings-inc-lawsuit-submission-form-2?prid=166642&wire=4 Accessibility StatementSkip Navigation NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus Holdings, Inc." or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus Holdings, Inc. investors who were adversely affected by alleged securities fraud between February 2 ...

Core Viewpoint - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Lantheus Holdings, Inc. due to allegations of providing misleading business information to investors [1]. Company Overview - Lantheus Holdings, Inc. is a globally recognized company focused on the development, production, and distribution of advanced diagnostic and therapeutic products, with core expertise in oncology and cardiovascular care [3]. Alleged Wrongdoing - On August 6, 2025, Lantheus reported weaker-than-expected second-quarter results, missing earnings and revenue targets. The company cut its full-year 2025 revenue and EPS forecasts, citing tougher competition in the PSMA PET imaging market and strategic pullbacks from certain accounts [4]. - Revenue for the quarter fell to $378 million, down 4.1%, with PYLARIFY sales dropping 8.3% to $250.6 million, both below projections [4]. Market Reaction - Following the news of the disappointing results, Lantheus stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 11, 2025 (GLO ...

Sep 11, 2025 3:45 PM Eastern Daylight Time NASDAQ: LNTH: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Lantheus Holdings, Inc. Share RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus†) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26 ...

Core Viewpoint - Lantheus Holdings, Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is being conducted by the Law Offices of Frank R. Cruz on behalf of investors [1] - The investigation follows the release of Lantheus's first quarter 2025 financial results on May 7, 2025 [1]

Core Viewpoint - Lantheus Holdings, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the performance and pricing of its key product, Pylarify, which has led to significant stock price declines [3]. Group 1: Legal Action - The Portnoy Law Firm is advising Lantheus investors who purchased securities between February 26, 2025, and August 5, 2025, to file a lead plaintiff motion by November 10, 2025 [1]. - Investors can contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations and Impact - The complaint claims that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, asserting that market leadership and premium pricing would support revenue growth while concealing competitive pressures [3]. - Following the release of quarterly results in May and August 2025, which showed sharp sales declines and reduced guidance, Lantheus' stock dropped over 23% and 28% respectively [3].

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Lantheus business and prospects, resulting in its stock trading at inflated prices. ...

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/ ...

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased Lantheus securities between February 26, 2025, and August 5, 2025 [2]. Case Details - The Complaint alleges that Lantheus made materially false and misleading statements, including: - Providing overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The early 2025 price increase, despite prior price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and revenue [3]. - Defendants' statements regarding the Company's business and prospects were materially false and misleading [3]. Next Steps - Investors who suffered losses in Lantheus have until November 10, 2025, to request to be appointed as lead plaintiff in the case [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025. Lantheus describes itself as a "global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products.†For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. ...